Liquid Biopsy Markets: Global Analysis and Opportunity Evaluation 2016 - 2020

Friday, January 27, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, Jan. 26, 2017 /PRNewswire/ -- This market report gives a comprehensive and easy-to-review analysis of the liquid

biopsy market 2016 – 2020. It provides key market data and identifies new and emerging opportunities relating to circulating tumour cells (CTCs) and circulating cell-free DNA and RNA (cfDNA and cfRNA). The analysis is based on primary data disclosed
by experienced end-users' in the clinical, diagnostics and research fields on their current liquid biopsy practices and their plans over the next three. Its findings provide a wealth of market information on the liquid biopsy market and enables suppliers to reduce costs, identify new markets and compete more effectively in the global marketplace.Circulating Tumour Cells (CTCs)Current and 3-year CTC activity disclosures provided by 482 scientists and cliniciansGrowth in CTC tests and estimated growth over the next 3 years (±% change)End-users' estimates of the costs per patient, for CTC testsCTC detection/enrichment platforms used currently and in 3 years (±% change)Company CTC platforms used currently and over the next 3 years (±% change)CTC parameters or measurements now and in 3 years (±% change)Non-Molecular techniques used with CTCs, currently and in 3 years (±% change)Molecular techniques used with CTCs, now and in 3 years (±% change)Suppliers of molecular techniques currently and anticipated in 3 years (±% change)Markers used to enrich or characterise CTCs now and in 3 years (±% change)CTC subpopulation studies currently and anticipated in 3 years (±% change)Molecular forms studied currently and anticipated in 3 years (±% change)Molecular biomarkers studied currently and anticipated in 3 years (±% change)Sample types studied currently for the purpose of CTC studiesEnd-users' disclosures on the clinical utilities of CTCs in diagnosticsCancer types studied relating to the study of CTCsPurpose of studies relating to CTCsLimitations of current studies of CTCsFields or sectorsGlobal regions, countries and organisation typesThe study or investigation of CTCs in drug R&DThe study or investigation of CTC in drug R&D by R&D development phaseThe use of CTCs as companion diagnostics now and in 3 years (±% change)Free Circulating Nucleic Acids (CNAs)Growth in cfDNA and cfRNA tests and over the next 3 years (±% change)Cost estimates per sample, by scientists and clinicians, for patient CNA testsMolecular techniques used with cfDNA and cfRNA, now and in 3 years (±% change)Suppliers of molecular techniques currently and anticipated in 3 years (±% change)Suppliers of kits for the enrichment or isolation of cfDNA and cfRNAMolecular forms studied currently and anticipated in 3 years (±% change)Biomarkers studied currently and anticipated in 3 years (±% change)Sample types studied for cfDNA and cfRNA now and in 3 years (±% change)Clinical utilities of cfDNA and cfRNA in diagnostics now and in 3 years (±% change)Disease types studied relating to the study of cfDNA and cfRNACancer types studied relating to the study of cfDNA and cfRNAPurpose of studies relating to cfDNA and cfRNALimitations of current studies of cfDNA and cfRNAFields or sectorsGlobal regions, countries and organisation typesEnd-users' cfDNA and cfRNA studies in drug R&D now and 3 years (±% change)End-users' cfDNA and cfRNA studies in drug R&D by R&D development phaseThe study of cfDNA/cfRNA for companion diagnostics now and in 3 years (±% change)ExosomesThe study of exosomes by end-users now and 3 years (±% change)Disease areas relating to the study of exosomesPreferred kits and suppliers for the isolation of exosomesThis ReportRecent years have seen the rapid development of minimally invasive diagnostic techniques in the cancer field, notably relating to so-called 'liquid biopsies'. These developments have included the study and characterisation of circulating tumour cells and (CTCs) and circulating cell-free nucleic acids (cfDNA and cfRNA). Today, around 50 companies offer techniques that image, enrich, isolate or characterise CTCs and more advanced methods are also being used to isolate and characterise cfDNA and cfRNA. Advances are also being seen in the study of CTC sub-populations, time-dependent changes and the markers used to isolate or enrich them and new methods are increasingly being applied to cfDNA and cfRNA. Both of these strategies are seeing rapid development, as researchers and developers seek to translate these methodologies and the findings they are providing, into diagnostic tests that impact on clinical care or which drive new discovery.Nevertheless, despite the excitement these developments are creating, important and fundamental questions remain unanswered. Laboratory Markets Ltd has carried out two comprehensive studies of diagnostic developments relating to CTCs, cell-free nucleic acids (cfDNA and cfRNA) and exosomes. These were carried out to help address these questions and to assist diagnostic companies to identify and support evolving diagnostic needs in these growing fields.This report presents the findings of a new 'liquid biopsy' market study on CTCs, circulating cell-free nucleic acids and exosomes, completed in December 2015. These findings are analysed alongside results of a study of these markets, completed eighteen months earlier. Findings from these two studies, which present the disclosures of experienced researchers and clinicians in these fields, allowed an in-depth analysis of new developments and trends being seen in these growing diagnostic market areas.The current studies profiled 482 experienced clinicians and research scientists, and covered CTC and cfDNA and cfRNA current practices, developments, trends and three-year plans, as well as growth, shrinkage and opportunities across key areas of these diagnostic markets. Its findings provide diagnostic companies with market information on the current and evolving use or CTCs and cfDNA and cfRNA, as well as exosomes, and the techniques that are driving these developments.Our specialised market studies are designed to assist diagnostic companies and developers to profile current and evolving market opportunities. All of our studies are carried out through specialist groups of experienced researchers and clinicians, and therefore findings are based on 'real world' market data. By providing new insights and a better understanding of end-user practices, needs and future plans, our studies help companies identify qualified leads, to sell into these markets and also support innovation and strategic planning.Companies mentionedMore than 120 companies are mentioned in this report, namely A&A Biotechnology, AB ANALITICA, Abbott, Abcam, ABI, Abnova, ABSciex, AccuGenomics, Aczon, Adnagen, Advanced Cell Diagnostics, AdvanDx, Affymetrix, Agendia, Agilent, ALS Jena, AMNIS, Amoy Diagnostics, Angle Technology, Applied Biosystems, Argene Inc (Biomerieux), Arrayit, Asuragen, Axis Shield, Axygen Products, Bayer, BD, Beckman Coulter, Becton Dickinson, Biocept, BioGenex, BioLegend, Bioline, Biometra, Bioneer, Bio-Rad, Biovendor, Bioview, Cancer Genetics, Canopus, Caris Life Sciences, Cell Search, Cell Signaling Technology, Chemicon, Clarient, Compucyte, Cynvenio, Cytocell, Dako (Agilent), Dianova, Dynam, eBiosciences, Empire Genomics, Enzo Life Sciences, Epic Sciences, Eppendorf, Eurofins, Eurogentec, Euroimmun, Falcon Genomics, Fermantas, Filtini, Fluidigm, Fluxion, Foundation Medicine, GE Healthcare, Genetix, GenMark Diagnostics, Greiner Bio-One, IDEXX, IDT, IDVET, Ikonisys, Illumina, Interpath, Invitrogen, Invitrogen (Life Technologies), Ipsogen (Qiagen), Janssen-Veridex, Leika, Life Technologies, Luminex, Merck, MetaCell, Millipore, Miltenyi Biotech, Molecular Devices, MolecularMD, MP-Biomedicals, Myriad Genetics, Nanostring, New England Biolabs, Olink, Ortho, Oxoid, Pathology, Peqlab, Perkin Elmer, Peviva, Promega, Qiagen, R&D, Rarecells, Roche, Roche Diagnostics, Santacruz, ScreenCell, Shimadzu, Siemens, Sigma Aldrich, Silicon Systems, Stemcell Tech, StemCell Technologies, Sysmex, Takara, ThermoFisher, TiBMolBiol, Ventana (Roche), Viatar CTC Solutions, Vitatek, VWR, Zeiss and Zymo Research.Circulating Tumour Cells1. Growth: Based on recent trends in the number of CTC tests (i.e. number of assays) carried out in their laboratory:Study Dec 2015: Participants estimates of by how much (% increase or % decrease) their laboratory's work with CTCs has changed (or not) over the last three years. Also, based on current trends in the number of CTC tests (i.e. number of assays) carried out in your laboratory, participants estimates by how much (% increase or % decrease) they anticipate their CTC activities will change (or not) over the next three years.Study1 2014: Participants estimates of by how much (% increase or % decrease) their laboratory's work with CTCs has changed (or not) over the last three years. Also, based on current trends in the number of CTC tests (i.e. number of assays) carried out in your laboratory, participants estimates by how much (% increase or % decrease) they anticipate their CTC activities will change (or not) over the next three years.2. CTC Test CostsStudy Dec 2015: End-users' estimates of current per-patient test costs for CTCs.Study1 2014: End-users' estimates of current per-patient test costs for CTCs.3. CTC Detection & Enrichment: The main CTC enrichment, isolation or detection methods (and the associated suppliers) they use in their current activities and, based on current trends or developments in their work, the main CTC enrichment, isolation or detection methods they anticipate using in their work in three years from now. The methods and suppliers considered were:Study Dec 2015: Abnova CytoQuest™, ADNAGEN: Immunomagnetic (Adnatest®), Advanced Cell Diagnostics: CTCscope™, Affymetrix: ViewRNA CTC Kit, ALS Jena: AVISO CellCelector, AMNIS: Flow Cytometry (ImageStreamX, APOCELL: Dielectrophoretic fractionation (ApoStream®), AVIVA BIOSCIENCES: RBC/WBC depletion (Enrichment Kit), Beckman Coulter (MoFlo Astrios EQ Series), BIOCEP: Immunomagnetic (CEPir), BIOCEPT (OncoCEE-BR™), BIOFLUIDICA: Microfluidic capture bed, BIOVIEW: Scanning FISH probes (T-FISH), CANOPUS BIOSCIENCE: By visoelectric properties (CTC Platform), CELL RAFFIX: CellSelect, CELULA: Cell sorter (Mvs360), CLEARBRIDGE: Microfluidic trapping (ClearCell®), COMPUCYTE CORPORATION: Fluorescence microscopy (Maintrac®), CREATV MICROTECH: Microfilters (CellSieve™), CYNVENIO BIOSYSTEMS: Immunomagnetic (CT-QUANT), Cytomag: Rare Cells Systems™, CYTOTRACK: Detection without enrichment (CytoTrack CT4), DENOVO SCIENCES: Microfluidic, DMB Diagnostics: Maintrac®, DYNAL/THERMOFISHER: Magnetic beads (Epithelial Enrich™), EPIC SCIENCES: Caputure and imaging (Aqua™ glass slide), FACS (Any Supplier), FILTINI: Microfilter technology, FLUIDIGM: Single-cell Genomics (BioMark™), FLUXION BIOSYSTEMS: Microfluidic technology (IsoFlux), GE HEALTHCARE: Cell Density-Based (Ficoll), GENETIX ARIOL/MOLECULAR DEVICES: Automated cell imaging, GREINER BIO-ONE: Cell Gradient (OncoQuick®), IKONISYS: Imaging (Ikoniscope(TM) System), IV DIAGNOSTICS: IVDxTx platform real-time monitoring, JANSSEN (VERIDEX): Immunomagnetic (CELLSEARCH® CTC Test), Janssen- CTC-iChip, Massachusetts Gen Center: CTC-iCHIP, MetaCell: MetaCell® Tube – Based Test, METHODIST HOSPITAL RESEARCH: Aptamers and flurorescence, MILTENYI BIOTECH: Magnetic beads (MACS® Technology), ONCOLYS: Telomerase-positive cells (TelomeScan®), Own (in-house) device(s), Parsortix (Angle Technology), RARECELLS: Size-based (ISET®), RARECYTE: Immunomagnetic (AccuCyte™), SCREENCELL: Size-based (ScreenCell®), SILICON BIOSYSTEMS: Image-based (DEPArray™), SRI Biosciences' FASTcell system., Stemcell Tech: Lymphoprep/RosetteSep™, SYNERGX CORPORATION: Polymer-Antibody (PACS™), SYSMEX: Fluorescence emission (TelomeScan®), Thermo Fisher/Cynvenio Immunomagnetic (CT-QUANT), UNIVERSITY, MONTPELLIER: Proteins from cancer cells (Epispot), Viatar CTC Solutions: ViatarTM Molecular Diagnostics System, VIATOR LAB: Photoacoustic Detection, VITATEX: Cell Adhesion matrix Technology (CAM), Vortex Biosciences: CTC Isolation Platform and others.Study1 2014: ADNAGEN: Immunomagnetic (Adnatest®), ADVANCED CELL DIAGNOSTICS: Detection (RNAscope®, AMNIS: Flow Cytometry (ImageStreamX, APOCELL: Dielectrophoretic fractionation (ApoStream®), AVIVA BIOSCIENCES: RBC/WBC depletion (Enrichment Kit), BIOCEP: Immunomagnetic (CEP), BIOCEPT LABORATORIES: Immunocytochemical (OncoCEE-BR™), BIOFLUIDICA: Microfluidic capture bed, BIOVIEW: Scanning FISH probes (T-FISH), CANOPUS BIOSCIENCE: By viscoelastic properties (CTC Platform), CELL TRAFFIX: Capture and imaging, CELULA: Cell sorter (Mvs360), CLEARBRIDGE: Microfluidic trapping (ClearCell®), CREATV MICROTECH: Microfilters (CellSieve™), CYNVENIO BIOSYSTEMS: Immunomagnetic (CT-QUANT), CYTOTRACK: Detection without enrichment (CytoTrack CT4), DENOVO SCIENCES: Microfluidic, DYNAL: Magnetic beads (Epithelial Enrich™), EPIC SCIENCES: Caputure and imaging (Aqua™ glass slide), FILTINI: Microfilter technology, FLUIDIGM: Single-cell Genomics (BioMark™), FLUXION BIOSYSTEMS: Microfluidic technology (IsoFlux), GE HEALTHCARE: Cell Density-Based (Ficoll), GENETIX ARIOL/MOLECULAR DEVICES: Automated cell imaging, GREINER BIO-ONE: Cell Gradient (OncoQuick®), IKONISYS: Imaging (Ikoniscope™ System), IV DIAGNOSTICS: Real-time monitoring, JANSSEN (VERIDEX): Immunomagnetic (CELLSEARCH® CTC Test), COMPUCYTE CORPORATION: Fluorescence microscopy (Maintrac®), MILTENYI BIOTECH: Magnetic beads (MACS® Technology), METHODIST HOSPITAL RESEARCH: Aptamers and flurorescence (ODOSA), ONCOLYS: Telomerase-positive cells (TelomeScan®), ANGLE TECHNOLOGY: Filter (Parsortix), RARECELLS: Size-based (ISET®), RARECYTE: Immunomagnetic (AccuCyte™), SCREENCELL: Size-based (ScreenCell®), SILICON BIOSYSTEMS: Image-based (DEPArray™), SRI INTERNATIONAL: Array scanning (FAST), STEMCELL TECHNOLOGIES: Immunodensity (RosetteSep™), SYNERGX CORPORATION: Polymer-Antibody (PACS™), SYSMEX: Fluorescence emission (TelomeScan®), UNIVERSITY, MONTPELLIER: Proteins from cancer cells (Epispot), VIATOR LAB: Photoacoustic Detection, VITATEX: Cell Adhesion matrix Technology (CAM) and any others.4. Non-Molecular Techniques: The main non-molecular characterisation techniques that participants currently use in their CTC studies and, based on current trends or developments in their work, the main non-molecular characterisation techniques that participants anticipate using in their CTC studies in three year from now. The techniques considered included:Study Dec 2015: Antibody tests, Bioluminescence, Cell arrays, Chemiluminescence, Chromatography, Densitometry, Electrophoresis, Enzyme assays, Filtration, Flow cytometry, Imaging, Immunoassay, Immunocytochemical, Mass Spectrometry, Microarrays, Microscopy, Radioimmunoassay, Ultrasonography, Western Blot and any others.Study1 2014: Antibody tests, Bioluminescence, Chemiluminescence, Chromatography, Electrophoresis, Enzyme assays, Flow cytometry, Imaging, Immunoassay, Immunocytochemical, Mass Spectrometry, Microarrays, Microscopy, Radioimmunoassay, Cell arrays, Ultrasonography, Western Blot and any others.5. Suppliers of Non-Molecular Techniques: Participants current suppliers (of systems, kits, reagents) of their non-molecular methods used in their CTC investigations and, based on current trends or developments in their work, who they anticipate will be your main suppliers of your non-molecular methods (e.g. Systems, kits, reagents) relating to your CFTC investigation in three years from now (the 2014 study only).6. Molecular Techniques: The main molecular characterisation techniques that participants currently use, in your CTC studies and, based on current trends and developments in their work, the main molecular characterisation techniques that they anticipate using in their CTC studies in three year from now. The techniques considered were:Study Dec 2015: Allele-specific PCR, Arbitrarily Primed PCR (AP-PCR), Assembly PCR (Polymerase Cycling Assembly, PCA), Asymmetric PCR (A PCR), bDNA assays, Bead-Emulsion Amplification PCR (BEA), Cancer BioChip System, Classical qualitative PCR, Colony PCR, Comet assay, Conventional qualitative PCR, Cycling Probe Technology, Cytogenetic banding, Degenerate Oligonucleotide PCR (DOP-PCR), Denaturing Gradient Gel Electrophoresis (DGGE), Digital PCR (dPCR), DNA biosensors, DNA cloning, General Hybridization, General Primers PCR, Genome Expression Profiling System (GeXP), Helicase-Dependent Amplification, High resolution melting (HRM), Hot start PCR, Hybrid Capture Assay, Hyper-PCR, Immunocapture PCR, In Situ Hybridization (e.g. FISH), In-Silico PCR, Intersequence-specific PCR (ISSR), Inverse PCR, Isothermal PCR, Karyotyping (chromosomes), Ligase Chain Reaction, Ligation-Mediated PCR, Liquid Hybridization, LNA PCR, Long PCR, Loop-mediated isothermal amplification (LAMP), Methylation-Specific PCR (MSP), Microarrays, Microsphere-Based Array, Miniprimer PCR, Multilocus Sequence Typing (MLST), Multiple Loci VNTR Analysis (MLVA), Multiplex Ligation-Dependent Probe Amplification (MLPA), Multiplex PCR, Multiplex Real-Time PCR, Multiplex Taqman, Multiplexed Microsphere-Based Array, Nested PCR, Next-Generation Sequencing (NGS), Northern Blot, Nucleic Acid Sequence-Based Amplification (NASBA), Other, Overlap-Extension PCR ( Splicing by overlap extension, SOE), PAN-AC (Single Reaction Real Time PCR), Panbacterial PCR, PCR array, PCR Denaturing Gradient Gel Electrophoresis (PCR DGGE), PCR Restriction Fragment Length Polymorphism (PCR-RFLP), Phylogenetic Community Analysis, Pulsed Field Gel Glectrophoresis (PFGE), Random Amplified Polymorphic DNA (RAPD), Rapid Amplification of cDNA ENDS PCR (RACE PCR), Rapid test, Real Time/Quantitative PCR (qPCR), Restriction Fragment Length Polymorphism (RFLP), Reverse Transcription PCR (RT-PCR), RNA-seq (Whole Transcriptome), Sanger sequencing, Single molecule PCR, Single nucleotide repeat (SNR), Single Specific Primer-Polymerase Chain Reaction (SSP-PCR), Single tube Nested-PCR, Solid Phase PCR, Southern Blot, Stem loop RT PCR, Stepdown PCR, Strand Displacement Amplification, TaqMan Real Time PCR, Techniques not requiring amplification, Temporal Temperature Gradient Gel Electrophoresis (PCR-TTGE), Thermal Asymmetric Interlaced PCR (TAIL-PCR), Touchdown PCR, Transcription-Mediated Amplification (TMA), Type-Specific PCR, Universal Fast Walking, Whole genome amplification, Other and Other (please specify).Study 1 2014: Allele-specific PCR, Arbitrarily Primed PCR (AP-PCR), Assembly PCR (Polymerase Cycling Assembly, PCA), Asymmetric PCR (A PCR), Bead-Emulsion Amplification PCR (BEA), Classical qualitative PCR, Colony PCR, Degenerate Oligonucleotide PCR (DOP-PCR), Digital PCR (dPCR), DNA cloning, Hot start PCR, Immunocapture PCR, In Situ Hybridization (e.g. FISH), In-Silico PCR, Inverse PCR, Isothermal PCR, Ligation-Mediated PCR, Long PCR, Methylation-Specific PCR (MSP), Microarrays, Miniprimer PCR, Multiplex Ligation-Dependent Probe Amplification (MLPA), Multiplex PCR, Multiplex Real-Time PCR, Multiplex Taqman, Nested PCR, Next-Generation Sequencing, Northern Blot, PAN-AC (Single Reaction Real Time PCR), PCR array, PCR Denaturing Gradient Gel Electrophoresis (PCR DGGE), PCR Restriction Fragment Length Polymorphism (PCR-RFLP), Real time PCR (qPCR), Random Amplified Polymorphic DNA (RAPD), Rapid Amplification of cDNA ENDS PCR (RACE PCR), Reverse Transcription PCR (RT-PCR), Sequencing (Sanger), Single molecule PCR, Single Specific Primer-Polymerase Chain Reaction (SSP-PCR), Solid Phase PCR, Southern Blot, Stem loop RT PCR, Taqman, Temporal Temperature Gradient Gel Electrophoresis (PCR-TTGE), Touchdown PCR, Transcription-Mediated Amplification (TMA) and other techniques.7. Molecular Suppliers: The main current suppliers (molecular systems, kits, reagents of molecular methods (e.g. Systems, kits, reagents), relating to participant's CTC investigations and, based on current trends or developments in their work, the main suppliers of molecular methods (e.g. Systems, kits, reagents) that participants anticipate purchasing from in three years from now. The organisations considered wereStudy Dec 2015: A&A Biotechnology, AB ANALITICA, Abbott Molecular, Abcam, AccuGenomics, AdvanDx, Affymetrix, Agendia, Agilent, Alere (ClonDiag), Ameripath, Amoy Diagnostics, Amplisens, APB, Applied BioCode, Applied BioSystems (ABI), Arcxis Biotechnologies, Argene Inc (Biomerieux), Arrayit, Asuragen, Atlas Genetics, AutoGenomics, Axygen Products, Bayer, BD, Beckman Coulter, Biocartis, Biocept, Biodynamics, Biodyne, BioGenex, Biognost, BioHelix, Bioline, BioMerieux, Biometra, Bioneer, Bio-Rad, Bruker, Cancer Genetics, Caris Life Sciences, Cell Biolabs, Cell Signaling Technology, Cell-Marque, Cepheid, Clarient, Conda, Cooperative Diagnostics, Cytocell, Dako (Agilent), DDL, DermTech, ELITech Molecular, Empire Genomics, Enzo Life Sciences, Epigenomics, Eppendorf, Eurofins, Euroimmun, Experteem, Falcon Genomics, Fast track Diagnostics, Fermantas, Fluidigm, Focus Diagnostics, Foundation Medicine, GE Healthcare, Geneworks, GenMark Diagnostics, Genomica, Gen-Probe (Hologic), Gold Standard Diagnostics, Hain Life Science, Hemogenomics, Hologic, Hylabs, Idaho Technology, IDEXX, IDT, IDVET, Illumina, INBIO HIGHWAY, INEP, In-House Developed, Integrated Biotherapeutics, Interpath, Invitrogen (Life Technologies), Ipsogen (Qiagen), Kreatech Diagnostics, Lectinity, Leica, Life Technologies, Longgene, Luminex, Macherey-Nagel, MDxHealth, Merck, Meridian Bioscience, Metabion, Millipore, Mobio, MolecularMD, MP-Biomedicals, MRC-Holland, MWG Biotech, Myriad Genetics, Nanosphere, Nanostring, NeoGenomics, New England Biolabs, Novartis Diagnostics, Optigene, Orion Genomics, Other, OvaGene Oncology, Oxoid, Pacific Bioscience, Palex, Pathology, Peqlab, Primer Design, PrimeraDx, Promega, Qiagen, Quidel, R-Biopharm Inc, Roche Diagnostics, Sacace Biotechnologies, Santacruz, Seegene, SensiGen, Serosep Ltd., Shimadzu, Siemens, Sigma-aldrich, SinaGen, Solis Biodyne, Stratagene, Synbiotics, Sysmex, Takara, Thermo Fisher, TiBMolBiol, TwistDx, Ventana (Roche), Vircell, Virion, Vivantis, VWR, Zymo Research and Other.Study1 2014: Abbott Molecular, AccuGenomics, AdnaGen, Affymetrix, Agendia, Amoy Diagnostics, Arcxis Biotechnologies, Arrayit, Asuragen, Autogenomics, Bayer, BD, Beckman Coulter, Biocartis, Biocept, BioGenex, BioHelix, bioMerieux, bioTheranostics (AviaraDx), Cancer Genetics, Inc, Cepheid, Chronix Biomedical, Cooperative Diagnostics, Cytocell, Da An Gene, Dako (Agilent), DermTech, Epigenomics, Gen-Probe, Hologic, Illumina, Invitrogen, Ipsogen (Qiagen), Kreatech Diagnostics, Luminex, MDxHealth, MolecularMD, Myriad Genetics, NeoGenomics, Novartis Diagnostics, Orion Genomics, Ortho-Clinical Diagnostics, OvaGene Oncology, PrimeraDx, Qiagen, Ribomed, Roche, SensiGen, Siemens, Sysmex, Thermo Fisher Scientific, Ventana (Roche) and any other organisations.Download the full report: https://www.reportbuyer.com/product/4653943/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.comFor more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/liquid-biopsy-markets-global-analysis-and-opportunity-evaluation-2016---2020-300397871.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook